Ovarian CarcinomaPhase 2NCT02487693
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
A Phase 2 study testing Radiofrequency ablation and Cytokine-induced killer cells in people with Ovarian Carcinoma, run by The First People's Hospital of Changzhou.
Trial summary
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma. Read more about this study
- Who is it for?
- Ages 30 to 70 years, women only
- Conditions the study is for
- Ovarian Carcinoma
- What is being tested?
- Radiofrequency ablation and Cytokine-induced killer cells
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- Jul 2015to Jun 2040
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 70 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients diagnosed with FIGO stage II ovarian carcinoma;
- cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed;
- medical records maintain comprehensive data on treatment and follow-up;
- no history of previous malignancies.
Who cannot join
- neoadjuvant chemotherapy applied;
- less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed;
- medical records maintain incomplete data on treatment or follow-up;
- history of previous malignancy.
About this study
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.
Read the detailed description
The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with ovarian carcinoma.
- Conditions
- Ovarian Carcinoma
- Being tested
- Radiofrequency ablation, Cytokine-induced killer cells
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Radiofrequency ablationProcedure or surgery
Also called RFA
Radiofrequency ablation is performed percutaneously under CT/US guidance
Cytokine-induced killer cellsBiological
Also called CIK
The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
| Study group | Role | What they receive |
|---|---|---|
| RFA alone | No intervention | Patients undergo radiofrequency ablation alone. |
| RFA+CIK | Experimental | Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions Receives: Procedure: Radiofrequency ablation; Biological: Cytokine-induced killer cells |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recurrence-free survival
Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.
Measured: 1 year
Secondary outcomes (1)
Adverse events
Adverse events related to RFA and CIK treatments.
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2015 (estimated)
- Study startJul 2015
- Primary completionJun 2038 (estimated)
- Study completionJun 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The First People's Hospital of Changzhou
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02487693
- Sponsor's protocol ID
- ovarian001
- Status last verified
- Feb 2016
- First submitted
- 29 Jun 2015
- Last updated
- 23 Feb 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
- ClinicalTrials.gov ID
- NCT02487693
- Acronym / sponsor ID
- ovarian001
- Conditions
- Ovarian Carcinoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- The First People's Hospital of ChangzhouUniversity, hospital or other
- Study start
- Jul 2015
- Primary completion
- Jun 2038 (estimated)
- Study completion
- Jun 2040 (estimated)
- First posted
- 1 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.
Detailed description
The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with ovarian carcinoma.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| RFA alone | No intervention | –Patients undergo radiofrequency ablation alone. |
| RFA+CIK | Experimental | Procedure: Radiofrequency ablation, Biological: Cytokine-induced killer cellsAutologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions |
Who may qualify
- Ages
- 30 to 70 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- patients diagnosed with FIGO stage II ovarian carcinoma;
- cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed;
- medical records maintain comprehensive data on treatment and follow-up;
- no history of previous malignancies.
Key exclusion criteria (4 listed)
- neoadjuvant chemotherapy applied;
- less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed;
- medical records maintain incomplete data on treatment or follow-up;
- history of previous malignancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Radiofrequency ablationAlso: RFARadiofrequency ablation is performed percutaneously under CT/US guidance | Procedure or surgery | RFA+CIK |
| Cytokine-induced killer cellsAlso: CIKThe patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment. | Biological | RFA+CIK |
Primary outcome
Recurrence-free survival
Time frame: 1 year
Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.
1 secondary outcome
Adverse events
Time frame: 4 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2016.
Related trials for Ovarian Carcinoma
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
RecruitingPhase 3
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Epithelial Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Radiofrequency ablation and Cytokine-induced killer cells in people with Ovarian Carcinoma, run by The First People's Hospital of Changzhou.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recurrence-free survival (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2016.